Rotator Cuff Repair (RCR) With and Without OrthoADAPT Augmentation
Launched by BAXTER HEALTHCARE CORPORATION · Aug 11, 2009
Trial Information
Current as of May 28, 2025
Withdrawn
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Ages 18-70
- • MRI confirmed full thickness or high grade partial thickness rotator cuff tear equal or more than 1 cm and involving the supraspinatus and/or infraspinatus tendons
- • Tear is repairable by surgery using protocol prescribed fixation procedure
- • Patient is able to sign and IRB approved study informed consent
- • Patient is willing and able to return for follow-up appointments and study related procedures
- • Patient is willing to comply with prescribed physical therapy regimen
- Exclusion Criteria:
- • Emergency, poly trauma patients
- • Prior same shoulder surgery including rotator cuff repair except prior subacromial decompression or distal clavicle resection
- • Shoulder pathology requiring concomitant procedures during the rotator cuff repair including Labral repair, anterior or posterior stabilization, and/or capsular plication or shift
- • Cervical spine disease
- • History of adhesive capsulitis in either shoulder
- • Patient whose injury does or may involve litigation
- • Diabetics
- • Rotator cuff tear cannot be repaired by primary surgical means including superiorly migrated humeral head, retracted rotator cuff that cannot be mobilized to humeral head, end stage tears, rotator cuff tissue cannot retain sutures, any comorbidities that would directly or indirectly affect the reparability of the cuff
- • Patients with grade 3 or 4 glenohumeral arthritis
- • Patients with systemic collage disease
- • Patients with a known hypersensitivity to equine derived materials
- • Active or latent infection
- • Chronic use of immunosuppressive agents
- • Any oral or IM NSAID usage within 5 days before surgery
- • Cancer patients
- • Decisional impaired patients
- • Pregnant women
About Baxter Healthcare Corporation
Baxter Healthcare Corporation is a global leader in the healthcare industry, dedicated to advancing medical innovation and improving patient outcomes through its comprehensive portfolio of products and services. With a strong focus on areas such as renal care, surgical solutions, and hospital products, Baxter leverages cutting-edge research and development to address the evolving needs of patients and healthcare providers. The company is committed to conducting high-quality clinical trials that adhere to rigorous ethical standards, ensuring the safety and efficacy of its therapies while fostering collaboration with healthcare professionals and regulatory bodies worldwide. Baxter's mission is to enhance the quality of life for patients through innovative and reliable healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seattle, Washington, United States
Patients applied
Trial Officials
Charles DePaolo, MD
Principal Investigator
Mission Health Research Institute
Pierce Scranton, MD
Principal Investigator
Seattle Medical Research Foundation
William Bryan, MD
Principal Investigator
Methodist Center for Orthopedic Surgery
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials